Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine

In Vivo

Volumn 17, Issue 2, 2003, Pages 181-184

  Ribeiro, Elisangela ^a   Lima, Carmen S P ^a   Metze, Konradin ^a   Souza, Carmino A ^a   Lorand Metze, Irene ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Amifostine; Apoptosis; CD34; Fas FasL; Myelodysplastic syndromes

Indexed keywords

AMIFOSTINE; CD34 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GLUCONATE CALCIUM; HEMOGLOBIN; METHYLPREDNISOLONE; ONDANSETRON; PROTEIN PRECURSOR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; BONE MARROW CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; IMMUNITY; LEUKOCYTE COUNT; LYMPHOCYTE; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; QUANTITATIVE ANALYSIS; RISK; THROMBOCYTE;

EID: 0038546514     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H, Rose S, Mativi BY, Gregory AS, Preiler HD and Raza A: The relative extent and propensity of CD34+ vs CD34 - Cells to undergo apoptosis in myelodysplastic marrows. Int J Haematol 9: 152-159, 1999.
2. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M and Colovic MD: Incidence and role of apoptosis in myelodysplastic syndrome: Morphological and ultrastructural assessment. Leukemia 11: 656-659, 1997.
3. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Dreyfus F and Fontenay-Roupie M: Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11: 839-845, 1997.
4. Deeg HJ, Cassandra B, Loken MR, Bryant E, Lennikova M, Shulman H and Gooley T: Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leukemia Res 37: 405-414, 2000.
5. Gersuk MG, Beckham C, Loken RM, Kiener P, Anderson EJ, Farrand A, Troutt B, Ledbetter AJ and Deeg JH: A role for tumor necrosis factor-alfa, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndromes. Br J Haematol 103: 176-88, 1998.
6. Maciejewski JP, Selleri C, Anderson S and Young NS: Fas antigen expression on CD34+ human marrow cells is induced by interferon-γ and tumour necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85: 3183-3190, 1995.
7. Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang RW and Raza A: Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrow of patients with myelodysplastic syndromes. Anticancer Res 19: 5323-5328, 1999.
8. Arboscello E, Botta M, Romero D, Schenone E, Mencoboni M, Bogliolo G and Pannaciulli I: Effects of retinoic acid and amifostine on in vitro growth of normal hemopoietic progenitor cells. Anticancer Res 21: 1139-1143, 2001.
9. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A,Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shar R, Kaizer H and Gregory S: Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 63: 265-78, 1996.
10. Galanopoulos A, Kritikou-Griva E, Gligori J, Michalis E, Grigoraki V, Marinakis T, Kakkas J, Tasiopoulou A and Anagnostopoulos NI: Treatment of patients with myelodysplastic syndrome with amifostine. Leukemia Res 25: 665-71, 2000.
11. List AF, Heaton R, Glisman-Gibson B and Capizzi R: Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23: 58-63 1996.
12. Arboscello E, Botta M, Bogliolo G, Clavio M, Miglino M, Mencoboni M and Pannaciulli I: Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome. Anticancer Res 22: 1819-1824, 2002.
13. List AF, Brasfield F, Heaton R, Glisman-Gibson B, Crook L, Taetle R and Capizzi RL: Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90: 3364-69, 1997.
14. List AF, Heaton R, Glisman-Gibson B and Capizzi RL: Amifostine stimulates formation of multipotent and erythroid marrow progenitors. Leukemia 12: 1596-1602, 1998.
15. Ribizzi I, Darnowski W and Goulett FA: Amifostine cytotoxicity and reduction of apoptosis in a human myelodysplastic cell line. Leukemia Res 24: 519-25, 2000.
16. Hofmann WK, Seipelt G, Ottmann OG, Koschmieder S, Brucher J, Frickhofen N, Klausmann M, Mitrou OS and Hoelzer D: Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumour necrosis factor alpha levels. Ann Hematol 79: 255-258, 2000.
17. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, Tassone P, Turco MC and Venuta S: Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κ B/Rel transcription factors. Blood 94: 4060-66, 1999.
18. Greenberg PL, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G and Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-88, 1997.
19. Tsouplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V and Zoumbos NC: Apoptosis in patients with myelodysplastic syndromes: Differential involvement of marrow cells in "good" versus "poor" prognosis patients and correlation with apoptosis-related genes. Leukemia 13: 1554-1563, 1999.
20. List AF: New approaches to the treatment of myelodysplasia. Oncologist 7(suppl 1): 39-49, 2002.
21. Peddie CM, Wolf CR, McLellan LI, Collins AR and Bowen DT: Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-a concentration. Br J Haematol 99: 625-631, 1997.
22. Bagby GC Jr, Gabourel JD and Linman JW: Glucocorticoid therapy in the preleukemic syndrome: Identification of responsive patients using in vitro techniques. Ann Intern Med 92: 55-58, 1980.
23. Kook H, Zeng WH, Chen GB, Kirby M, Young NS and Maciejewski JP: Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 29: 1270-1277, 2001.